PEComa Market: Analysis of Epidemiology, Pipeline Products, and Key Companies Working, DelveInsight | Sarcoma Oncology Research Center LLC, Aadi Bioscience Inc, Novartis Pharmaceuticals, CENTOGENE GmbH Rostock, Antia Therapeutics AG, InCor Heart Institute

PEComa emerging therapies such as FYARRO (sirolimus protein-bound), and others are expected to boost the PEComa Market in the upcoming years.

DelveInsight has launched a new report on "PEComa - Market Insights, Epidemiology, and Market Forecast-2034" that delivers an in-depth understanding of the PEComa, historical and forecasted epidemiology as well as the PEComa market trends in the United States, EU5 (Germany, Spain, Italy, France, and United Kingdom) and Japan.

Request for our pecoma market report sample page @ https://www.delveinsight.com/report-store/pecoma-market?utm_source=openpr&utm_medium=pressrelease&utm_campaign=kpr

Some of the key facts of the PEComa Market Report:

In 2023, the PEComa market in the United States was the largest among the seven major markets (7MM), valued at approximately USD 23 million, with projections indicating further growth by 2034.
In 2023, the United States had the largest share of PEComa incident cases, accounting for approximately 64% of the total cases across the seven major markets (7MM). In comparison, the EU4 and the UK made up about 28%, while Japan accounted for 8% of the total PEComa population.
The incidence of PEComa in the U.S. was estimated at around 250 cases in 2023, and this number is expected to increase during the forecast period (2024-2034).
Currently, Aadi Bioscience's FYARRO is the only FDA-approved therapy for PEComa.
In May 2022, Aadi Bioscience received a permanent, product-specific J-code (J9331) for FYARRO (sirolimus protein-bound particles for injectable suspension, albumin-bound), which became effective under the Healthcare Common Procedure Coding System (HCPCS) on July 1, 2022. This J-code facilitates insurance reimbursement for intravenous administration in adult patients with locally advanced, unresectable, or metastatic malignant PEComa.
Challenges in the PEComa market include low disease awareness and frequent misdiagnosis, which may slow market expansion. Additionally, FYARRO's high cost presents a potential barrier to widespread adoption. However, Aadi Bioscience is working to expand its PEComas by targeting a broader range of solid tumors with TSC1 or TSC2 mutations through its Phase II PRECISION 1 study, expected to complete full enrollment by mid-2024.
Early findings from the first 40 patients in the PRECISION 1 trial showed that 26% of patients with TSC1 mutations and 11% with TSC2 mutations achieved a partial response. While these results have been met with market disappointment, they still indicate some level of efficacy. Aadi Bioscience anticipates conducting a full analysis of the study in early 2025.
Currently, there are no emerging drugs in the PEComa pipeline, but market dynamics may shift in the coming years due to faster diagnosis and increased disease awareness. To drive market success, pricing strategies must also be carefully considered, ensuring that new treatments are both affordable and accessible for patients.
In 2023, the total PEComa treatment market size across the seven major markets (7MM) was estimated at approximately USD 25 million, with projections indicating growth throughout the 2024-2034 forecast period.
Among the EU4 countries, Germany had the largest PEComa treatment market size in 2023, while Spain recorded the lowest.
Key PEComa companies such as Sarcoma Oncology Research Center LLC, Aadi Bioscience Inc, Novartis Pharmaceuticals, CENTOGENE GmbH Rostock, Antia Therapeutics AG, InCor Heart Institute, Children's Hospital Medical Center, and others are evaluating new drugs for PEComa to improve the treatment landscape.
Promising PEComa pipeline therapies in various stages of development include FYARRO (sirolimus protein-bound), and others.
Key benefits of the PEComa market report:
PEComa market report covers a descriptive overview and comprehensive insight of the PEComa Epidemiology and PEComa market in the 7MM (the United States, EU5 (Germany, Spain, France, Italy, UK) & Japan.)
The PEComa market report provides insights on the current and emerging therapies.
PEComa market report provides a global historical and forecasted market covering drug outreach in 7MM.
The PEComa market report offers an edge that will help in developing business strategies by understanding trends shaping and driving the PEComa market.

Got queries? Click here to know more about the PEComa Market Landscape https://www.delveinsight.com/sample-request/pecoma-market?utm_source=openpr&utm_medium=pressrelease&utm_campaign=kpr

PEComa Overview

Perivascular epithelioid cell neoplasms (PEComas) are rare soft tissue tumors that typically develop around small blood vessels (perivascular spaces) in various organs, including the lungs, gastrointestinal tract, kidneys, liver, and uterus. These tumors consist of epithelioid (cuboidal) cells and exhibit characteristics similar to both melanocytes and smooth muscle cells. Melanocytes, commonly found in the skin, are responsible for producing melanin, which gives skin its pigment.

According to the WHO classification, PEComa NOS (not otherwise specified) includes both benign and malignant tumors. Among the more clinically challenging cases, oncologists frequently encounter abdominopelvic perivascular epithelioid cell sarcoma, commonly referred to as malignant PEComa.

Although PEComas are classified as a group of tumors, some subtypes exhibit distinct characteristics and have a higher likelihood of developing in specific body regions.

PEComa Market Outlook

PEComas are rare soft tissue tumors that typically develop around small blood vessels in various organs such as the lungs, GI tract, kidneys, liver, and uterus. Due to their rarity, there are no standardized guidelines for surgery, radiation therapy, or neoadjuvant/adjuvant treatments in malignant PEComa. Chemotherapy is primarily used for local recurrences and metastases, while mTOR inhibitors are the most commonly employed systemic therapy, used either curatively alongside surgery or radiotherapy or in palliative care.

The NCCN guidelines recognize sirolimus, temsirolimus, and everolimus as treatment options for advanced PEComa, though these recommendations are based on limited clinical data. However, traditional mTOR inhibitors have faced challenges such as poor pharmacokinetics, variable absorption, and limited tumor penetration, leading to suboptimal efficacy.

FYARRO (nab-sirolimus), approved in November 2021, offers improved tumor penetration and prolonged target suppression, making it more effective than other mTOR inhibitors.

Despite the lack of emerging therapies, the PEComa market is expected to evolve due to faster diagnosis, increased disease awareness, and strategic pricing considerations. These factors will play a crucial role in driving the development of market-fit treatments and expanding therapeutic options for PEComa patients.

Explore how the Pecoma market is rising @ https://www.delveinsight.com/report-store/pecoma-market?utm_source=openpr&utm_medium=pressrelease&utm_campaign=kpr

PEComa Marketed Drugs

FYARRO (sirolimus protein-bound): Aadi Bioscience

Scope of the PEComa Market Report

Study Period: 2020-2034
Coverage: 7MM [The United States, EU5 (Germany, France, Italy, Spain, and the United Kingdom), and Japan]
Key PEComa Companies: Sarcoma Oncology Research Center LLC, Aadi Bioscience Inc, Novartis Pharmaceuticals, CENTOGENE GmbH Rostock, Antia Therapeutics AG, InCor Heart Institute, Children's Hospital Medical Center, and others
Key PEComa Therapies: FYARRO (sirolimus protein-bound), and others
PEComa Therapeutic Assessment: PEComa current marketed and PEComa emerging therapies
PEComa Market Dynamics: PEComa market drivers and PEComa market barriers
Competitive Intelligence Analysis: SWOT analysis, PESTLE analysis, Porter's five forces, BCG Matrix, Market entry strategies
PEComa Unmet Needs, KOL's views, Analyst's views, PEComa Market Access and Reimbursement

Table of Contents

1. Report Introduction
2. Executive Summary
3. SWOT analysis
4. PEComa Patient Share (%) Overview at a Glance
5. PEComa Market Overview at a Glance
6. PEComa Disease Background and Overview
7. PEComa Epidemiology and Patient Population
8. Country-Specific Patient Population of PEComa
9. PEComa Current Treatment and Medical Practices
10. Unmet Needs
11. PEComa Emerging Therapies
12. PEComa Market Outlook
13. Country-Wise PEComa Market Analysis (2020-2034)
14. Market Access and Reimbursement of Therapies
15. Market drivers
16. Market barriers
17. Appendix
18. PEComa Report Methodology
19. DelveInsight Capabilities
20. Disclaimer
21. About DelveInsight

Click here to read more about PEComa Market Outlook 2034 https://www.delveinsight.com/sample-request/pecoma-market?utm_source=openpr&utm_medium=pressrelease&utm_campaign=kpr

Related Reports:

PEComa Pipeline Insights, DelveInsight

"PEComa Pipeline Insight, 2024" report by DelveInsight outlines comprehensive insights of present clinical development scenarios and growth prospects across the PEComa market. A detailed picture of the PEComa pipeline landscape is provided, which includes the disease overview and PEComa treatment guidelines.

Contact Info:

Kritika Rehani, Team Leader Marketing & Branding
krehani@delveinsight.com
info@delveinsight.com
www.delveinsight.com
+14699457679

About DelveInsight

DelveInsight is a leading Business Consultant and Market Research firm focused exclusively on life sciences. It supports Pharma companies by providing comprehensive end-to-end solutions to improve their performance.

This release was published on openPR.